Does Rallies show 13F holders for RAPP?

Yes. Rallies tracks hedge fund and 13F ownership data for RAPP, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RAPP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RAPP. It does not provide personalized investment advice.

RAPP (Rapport Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Rapport Therapeutics, Inc. Common Stock (RAPP) is a publicly traded Healthcare sector company. As of May 21, 2026, RAPP trades at $35.69 with a market cap of $1.68B and a P/E ratio of -13.51. RAPP moved +4.04% today. Year to date, RAPP is +29.80%; over the trailing twelve months it is +249.51%. Its 52-week range spans $6.43 to $42.27. Analyst consensus is strong buy with an average price target of $51.71. Rallies surfaces RAPP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RAPP stock?

Hedge funds tracked by Rallies that own RAPP include Soros Fund and Mangrove Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Rapport Therapeutics, Inc. Common Stock.

RAPP Key Metrics

Key financial metrics for RAPP
Metric	Value
Price	$35.69
Market Cap	$1.68B
P/E Ratio	-13.51
EPS	$-2.59
Dividend Yield	0.00%
52-Week High	$42.27
52-Week Low	$6.43
Volume	1
Avg Volume	0
Revenue (TTM)	$20.00M
Net Income	$-107.28M
Gross Margin	0.00%

Top Hedge Funds Holding RAPP

Soros Fund holds 30.00K shares of RAPP, changed +0.00% as of Jun 30, 2024.
Mangrove Partners holds 6.75K shares of RAPP, changed +0.00% as of Mar 31, 2026.

Latest RAPP News

Rapport Therapeutics’ RAP-219 Achieves 90% Seizure Reduction, Secures $476.8M Funding — May 7, 2026
Rapport Therapeutics Reports 77.8% Seizure Reduction, Eyes Phase 3 in Q2 2026 — Mar 10, 2026
Rapport Therapeutics' Lead ASM Forecast at $2.0 Billion Peak Sales — Mar 9, 2026
Rapport and Tenacia Secure $20M Upfront in $308M RAP-219 Collaboration in Greater China — Mar 9, 2026

Recent RAPP Insider Trades

Third Rock Ventures V, L.P. sold 133.62K (~$5.38M) on May 11, 2026.
Third Rock Ventures V, L.P. sold 5.02K (~$202.26K) on May 8, 2026.
Third Rock Ventures V, L.P. sold 271.50K (~$10.89M) on May 7, 2026.

RAPP Analyst Consensus

9 analysts cover RAPP: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.71.

Common questions about RAPP

Who owns RAPP stock?: Hedge funds tracked by Rallies that own RAPP include Soros Fund and Mangrove Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Rapport Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for RAPP?: Yes. Rallies tracks hedge fund and 13F ownership data for RAPP, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RAPP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RAPP. It does not provide personalized investment advice.